Montelukast drug activity and potential against severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2)
Open Access
- 13 July 2020
- journal article
- letter
- Published by Wiley in Journal of Medical Virology
- Vol. 93 (1) , 187-189
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- The association between obesity and poor outcome after COVID-19 indicates a potential therapeutic role for montelukastMedical Hypotheses, 2020
- Structure of the RNA-dependent RNA polymerase from COVID-19 virusScience, 2020
- Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitorsScience, 2020
- Montelukast, an Anti-asthmatic Drug, Inhibits Zika Virus Infection by Disrupting Viral IntegrityFrontiers in Microbiology, 2020
- Effects of montelukast on M2-related cytokine and chemokine in M2 macrophagesJournal of Microbiology, Immunology and Infection, 2018
- Alveolar Macrophages Prevent Lethal Influenza Pneumonia By Inhibiting Infection Of Type-1 Alveolar Epithelial CellsPLOS Pathogens, 2017
- The Effects of Montelukast on Antioxidant Enzymes and Proinflammatory Cytokines on the Heart, Liver, Lungs, and Kidneys in a Rat Model of Cecal Ligation and Puncture–Induced SepsisThe Scientific World Journal, 2011
- The leukotriene d4 receptor antagonist, montelukast, inhibits mast cell degranulation in the dermis induced by water avoidance stressActa Histochemica, 2009
- Empirical Scoring Functions for Advanced Protein−Ligand Docking with PLANTSJournal of Chemical Information and Modeling, 2009
- LEA3D: A Computer-Aided Ligand Design for Structure-Based Drug DesignJournal of Medicinal Chemistry, 2005